CJC-1295 with DAC 2mg

Description

Description & Mechanism

CJC-1295 with DAC is a synthetic analogue of growth hormone–releasing hormone (GHRH 1–29) that has been chemically modified through conjugation with a Drug Affinity Complex (DAC). The DAC moiety consists of a reactive linker designed to form a covalent association with circulating serum albumin, resulting in prolonged systemic persistence of the peptide in experimental systems. This bioconjugation alters pharmacokinetic behaviour while preserving the core peptide sequence responsible for receptor interaction.

In biochemical and cellular research models, CJC-1295 with DAC interacts with the GHRH receptor expressed on pituitary-derived cells, initiating intracellular signalling cascades associated with growth hormone secretion. Preclinical and clinical research studies have examined receptor activation dynamics, signalling duration, and downstream endocrine pathway engagement under extended exposure conditions. Observed molecular and physiological responses are dependent on experimental design, dosing paradigm, and model system, and are used to investigate prolonged GHRH receptor signalling rather than defined biological or physiological outcomes.

Applications in Research

• As a molecular probe to study GHRH receptor binding and activation dynamics.
• Investigation of growth hormone axis signalling and endocrine feedback mechanisms.
• In cellular assays examining downstream transcriptional and signalling responses.
• In preclinical or clinical research models assessing extended-duration peptide–receptor interaction resulting from albumin binding

Handling, Reconstitution & Stability

• Weigh under dry conditions; peptide is hygroscopic.
• Reconstitute in sterile water or appropriate buffered aqueous solution depending on assay requirements.
• Avoid vigorous agitation during dissolution due to peptide–DAC conjugation.
• Filter sterilize if required (e.g. 0.22 µm) immediately prior to use.
• Aliquot and store reconstituted solutions at –20 °C (or lower) to avoid repeated freeze–thaw cycles.
• Inspect solutions for precipitation or changes in clarity before use in sensitive assays.

Specifications Summary

Precautions & Notes

• Experimental behaviour of CJC-1295 with DAC is influenced by albumin binding, concentration, and dosing schedule.
• Buffer composition, pH, and ionic strength may affect peptide stability and assay performance.
• This compound was previously evaluated in clinical research settings; development was discontinued following precautionary termination unrelated to demonstrated peptide-specific toxicity.
• CJC-1295 has been reported in anti-doping and forensic literature; such classifications are unrelated to laboratory research use.
• Intended strictly for laboratory research use; not for human or veterinary application.